F-1: XORTX Therapeutics Launches $4M Public Offering

XORTX Therapeutics Inc. is offering up to 4,761,904 common shares, pre-funded warrants, and common warrants to raise approximately $3.8 million for R&D and working capital.

Summary

• Offering up to 4,761,904 common shares at an assumed public offering price of $0.84 per share, based on the Nasdaq closing price on September 22, 2025.
• Also offering 4,761,904 pre-funded warrants (exercise price $0.0001) and 4,761,904 common warrants (exercise price not less than the most recent TSXV closing price prior to pricing, expiring on the third anniversary of issuance).
• Each common share and pre-funded warrant will be sold together with one common warrant.
• Expected net proceeds of approximately $3.8 million, to be used for ongoing research and development activities, working capital, and general corporate purposes.
• The company is a late clinical-stage biotechnology firm focused on therapies for diseases modulated by aberrant purine and uric acid metabolism, including gout, autosomal dominant polycystic kidney disease (ADPKD), acute kidney injury (AKI) associated with respiratory virus infection, and type 2 diabetic nephropathy (T2DN).
• The lead program, XRx-026 for gout, has been prioritized for near-term marketing approval and revenue generation, with an NDA submission planned after a pharmacokinetic bridging study.
• The XRx-008 program for ADPKD has reported topline results from a bridging pharmacokinetic study, and discussions with the FDA suggest a single Phase 3 trial may be sufficient for accelerated approval.
• XRx-101 is a program to treat AKI associated with respiratory virus infection, and XRx-225 is a non-clinical stage program for T2DN.
• The company received a Nasdaq deficiency notice on April 17, 2025, for not meeting the minimum bid price requirement of $1.00, as its common shares closed below this price for 30 consecutive business days.
• Two non-brokered private placements closed in July and August 2025, raising aggregate gross proceeds of $925,000 and $114,500, respectively, through the issuance of units comprising common shares and warrants.
• IND preparation for the XRx-026 program was initiated on September 3, 2025, with submission anticipated in the second half of 2025.

Sentiment

Score: 4

Explanation: While the company is making progress in drug development and has a clear strategy, the immediate financial context of a 'reasonable best efforts' offering, Nasdaq non-compliance, and ongoing operating losses indicate significant financial risk and uncertainty for investors. The potential for dilution and lack of a trading market for warrants further dampens sentiment despite promising drug pipeline updates.

Positives

• Advancement of the XRx-026 gout program towards an NDA filing, targeting an estimated $700 million USD per year market opportunity based on inflation-adjusted Febuxostat peak sales.
• FDA responses clarified the remaining steps for XRx-026 NDA submission via the Section 505(b)(2) regulatory pathway, indicating a clear path forward.
• The XRx-008 program for ADPKD is eligible for accelerated approval with a single one-year Phase 3 clinical trial, potentially expediting market entry.
• Proprietary XORLO formulation demonstrates increased oral bioavailability, a key differentiator for improved patient outcomes.
• Granted patents in the U.S. and Europe cover xanthine oxidase inhibitor formulations and their use in treating insulin resistance and diabetic nephropathy, strengthening intellectual property.
• The TSX Venture Exchange has conditionally approved the company's listing application for the new shares and warrant shares, ensuring continued trading on that exchange.

Negatives

• The company's common shares are not in compliance with Nasdaq's minimum bid price requirement, trading at $0.84 compared to the required $1.00, leading to a deficiency notice and risk of de-listing.
• The offering is on a 'reasonable best efforts' basis, meaning there is no guarantee that the full target amount will be raised, which could hinder the company's ability to fulfill its business objectives.
• There is no established public trading market for the Pre-Funded Warrants or Common Warrants, and the company does not intend to list them, limiting their liquidity.
• The company has incurred operating losses and negative operating cash flow for the fiscal years ended December 31, 2024, and 2023.
• The offering will result in an immediate dilution of approximately $0.11 per common share to new investors.
• Management will have broad discretion in the application of the net proceeds from this offering, which may not always align with investor expectations or optimal outcomes.

Risks

• Inability to obtain additional financing to fund planned expenditures.
• Inaccuracy of estimates regarding expenses, future revenues, and capital requirements.
• Uncertainty regarding the success and timing of preclinical studies and clinical trials.
• Inability to obtain and maintain regulatory approval for product candidates (XORLO, XRx-026, XRx-008, etc.) and the labeling under any approval.
• Dependence on the performance of third-party manufacturers and contract research organizations.
• Inability to obtain and maintain intellectual property protection for product candidates.
• Challenges in successfully developing sales and marketing capabilities.
• Uncertainty of market acceptance for any future products.
• Competition from existing or future drugs that are or become available.
• Loss of key scientific or management personnel.
• Volatility of the common share market price due to various factors beyond the company's control.
• Risk of de-listing from Nasdaq due to failure to meet continued listing requirements, such as the minimum bid price.
• Lack of a liquid market for common shares, potentially making it difficult for purchasers to sell significant quantities without a price reduction.
• No established public trading market for Common Warrants or Pre-Funded Warrants, affecting their liquidity and pricing.
• Common Warrants may have no value if the common share price does not exceed their exercise price during the exercisable period.
• Holders of Common Warrants and/or Pre-Funded Warrants will have no rights as common shareholders until such warrants are exercised.
• The offering is conducted on a 'reasonable best efforts' basis, with no assurance that the offering will be fully consummated or that sufficient funds will be raised.
• Investing in the securities is speculative and involves a high degree of risk, with no assurance of any return on investment and potential for complete loss.
• Broad discretion of management in the application of the net proceeds from the offering.
• Future issuances of securities may result in substantial dilution to the purchasers of the securities in this offering.
• Potential adverse U.S. federal income tax consequences for U.S. Holders if the company is classified as a Passive Foreign Investment Company (PFIC).

Future Outlook

The company aims to accelerate its lead gout program (XRx-026) towards an NDA filing in the second half of 2025, targeting marketing approval and revenue generation. It also plans to advance XRx-008 for ADPKD to a Phase 3 clinical trial, which may be eligible for accelerated approval. The company intends to leverage its pipeline-in-a-product strategy to develop additional proprietary formulations of xanthine oxidase inhibitors and/or uric acid lowering agents to treat select renal indications and complement its activities through acquisitions or in-licensing opportunities in nephrology and diabetes when opportunities arise.

Management Comments

• "The first half of 2025 has been marked by intense focus and significant advancement, solidifying a robust plan to accelerate the lead gout program towards an NDA filing, aiming to propel technology toward revenue generation and foster substantial shareholder value." (Allen Davidoff, President and Chief Executive Officer, August 7, 2025)
• "XORLO, an oral oxypurinol formulation, shows increased oral bioavailability, a key differentiator for improved patient outcomes." (Allen Davidoff, President and Chief Executive Officer, August 7, 2025)
• "The XRx-026 program is approximately 12 months from filing a NDA (New Drug Application) with the US Food and Drug Administration (the FDA) for XORLO marketing approval, targeting an estimated USD $700 million per year market opportunity (considering the inflation-adjusted Febuxostat peak sales)." (Allen Davidoff, President and Chief Executive Officer, August 7, 2025)

Industry Context

XORTX Therapeutics operates in the biotechnology sector, specializing in therapies for diseases linked to aberrant purine and uric acid metabolism. Its 'pipeline-in-a-product' strategy, which involves developing innovative formulations of oxypurinol, aims to address unmet medical needs across various indications such as gout, ADPKD, AKI, and T2DN. This approach seeks to differentiate its offerings in competitive therapeutic markets by enhancing existing drug properties and targeting multiple diseases with a core technology. The company's focus on both orphan diseases (like ADPKD) and more prevalent conditions (like T2DN) is a common biotech strategy to balance market size with potentially faster regulatory pathways.

Comparison to Industry Standards

• The estimated $700 million per year market opportunity for XRx-026 (gout) is benchmarked against 'inflation-adjusted Febuxostat peak sales,' indicating a direct comparison to a known competitor in the gout treatment market.
• The company's strategy to pursue accelerated approval for XRx-008 (ADPKD) with a single one-year Phase 3 trial, following FDA discussions, aligns with regulatory pathways designed to expedite therapies for serious conditions with unmet needs, which is a common practice for orphan drug development.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceeding is pending or, to the company's knowledge, threatened against or affecting the company or its properties which, if there were an unfavorable decision, would individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, except as set forth in the SEC Reports.
• No director or officer is or has been the subject of any proceeding involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty.
• There is no pending or contemplated investigation by the Commission involving the company or any current or former director or officer.
• The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the company under the Exchange Act or the Securities Act.

Related Party Transactions

• Except as set forth in the SEC Reports, none of the executive officers or directors of the company, nor to the company's knowledge, any employees, are presently a party to any transaction with the company (other than for services as employees, executive officers, and directors), including any contract, agreement, or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any executive officer, director, or such employee or, to the knowledge of the company, any entity in which any executive officer, director, or any such employee has a substantial interest or is an officer, director, trustee, shareholder, member, or partner, in each case in excess of $120,000, other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the company, and (iii) other employee benefits, including stock option agreements under any stock option plan of the company.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution from the current offering and future issuances. Risk of de-listing from Nasdaq could negatively impact share price and liquidity. Warrants may have no value if the share price does not exceed the exercise price.
• **New Investors**: Will experience an immediate dilution of approximately $0.11 per share.
• **Employees/Management**: Directors and officers are subject to lock-up agreements for 180 days following the closing of the offering. Stock options are granted under equity compensation plans.
• **Placement Agent**: Will receive a 7% cash fee, a 1% non-accountable expense allowance, and warrants to purchase 5% of the shares sold, along with a right of first refusal for future financings.
• **Creditors**: The company's ongoing operating losses and negative cash flow indicate a reliance on capital raises to fund operations, which could impact its ability to service debt if not successful.

Next Steps

• Conduct a pharmacokinetic bridging study for the XRx-026 gout program.
• Submit a New Drug Application (NDA) to the FDA for XRx-026 marketing approval via the Section 505(b)(2) regulatory pathway.
• Initiate Phase 3 registration clinical trial testing for the XRx-008 ADPKD program.
• Plan future late-stage clinical studies targeting attenuation or reversal of AKI in hospitalized individuals with respiratory virus infection (XRx-101).
• Advance novel xanthine oxidase inhibitor (XOI) candidates for the XRx-225 program to treat T2DN.
• Identify other opportunities to leverage existing and new intellectual property.
• Prepare commercial supply of drug substance and drug product for XRx-026.
• Maximize the potential of the XRx-026 and XRx-008 product candidate programs, if approved, through independent commercialization and opportunistic collaborations.
• Leverage the pipeline-in-a-product strategy to develop additional proprietary formulations and pursue acquisitions or in-licensing opportunities in nephrology and diabetes.
• Evaluate all available options to resolve the Nasdaq minimum bid price deficiency and regain compliance with Nasdaq Rule 5550(a)(2).
• Submit the Investigational New Drug (IND) application for XRx-026 in the second half of 2025.
• Close the current public offering on or about the specified date in 2025.
• Apply to list all of the Shares and Warrant Shares on the Trading Market and promptly secure their listing.

Key Dates

Recommendation

The company has a promising pipeline of drug candidates and a clear development strategy, particularly with XRx-026 for gout showing near-term revenue potential and XRx-008 for ADPKD on an accelerated approval pathway. However, significant risks exist, including Nasdaq non-compliance, the 'reasonable best efforts' nature of the offering (implying funding uncertainty), ongoing operating losses, and potential for substantial dilution. The lack of a trading market for the warrants also limits their liquidity. A 'hold' recommendation is appropriate as the long-term potential is present, but current financial and market risks warrant caution and monitoring of execution on clinical milestones and financial stability.

Keywords

XORTX Therapeutics, Public Offering, Common Shares, Pre-Funded Warrants, Common Warrants, Biotechnology, Gout, ADPKD, AKI, T2DN, XORLO, Oxypurinol, Clinical Trials, NDA, FDA, Nasdaq, TSXV, Capital Raise, Dilution, Risk Factors, Financial Reporting, Corporate Governance